Rechallenged CR mice also presented marked downregulation of CD62L in splenic T cells, indicating an increase in the number of effector/memory T cells (Tem), a cardinal mediator of adaptive immunity responsible for long-term resistance to the recurrence of previously encountered tumors (Fig. 5e).72 Moreover, the serum levels of TNF-α, IFN-γ, and IL-6 were 1.4-, 1.33-, and 1.32-fold greater, respectively, in NanoTAC (+L)-treated CR mice than in naive mice on day 15 after tumor rechallenge (Fig. 5f). The gene discussed is SELL; the disease is neoplasm.